Related Experiment Videos
Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION-46L enhanced in vivo
1Laboratory of Diagnostic Radiology Research, CC, National Institutes of Health, Bethesda, Maryland 20892, USA.
Abstract:
MION-46L, a superparamagnetic iron oxide contrast agent, was investigated for its ability to increase the sensitivity of in vivo 3D MRI in the detection of brain lesions in a chronic experimental allergic encephalomyelitis (crEAE) mouse model. Lesion conspicuity on postcontrast 3D MRI was dramatically enhanced as compared to precontrast images corresponding to areas of inflammatory and demyelinating lesions. MION-46L could be detected on Prussian blue iron stain in the vascular endothelium, the perivascular space, and in macrophages within perivascular cuffs and areas of inflammation and demyelination. By taking advantage of the MION-46L induced macroscopic susceptibility effect, acute early lesions measuring only 100 microm in diameter could be detected. MION-46L enhanced MRI may be used to 1) provide a unique sensitivity in EAE lesion detection and correlate imaging to histopathology; 2) help to understand EAE lesion development and its underlying pathophysiology; and 3) eventually assist in preclinical screening of new experimental therapies directed at patients with multiple sclerosis (MS).
Insights
Superparamagnetic iron oxide contrast agent MION-46L significantly improved 3D MRI sensitivity for detecting brain lesions in a mouse model of multiple sclerosis (MS). This advance aids in understanding disease progression and preclinical therapy screening.
Area of Science:
- Neuroimaging
- Contrast Agent Development
- Immunology
Background:
- Chronic experimental allergic encephalomyelitis (crEAE) is a mouse model for studying multiple sclerosis (MS).
- Early and sensitive detection of brain lesions is crucial for understanding MS pathophysiology and evaluating therapies.
- Conventional MRI techniques may have limitations in detecting small or early-stage lesions.
Purpose of the Study:
- To evaluate the efficacy of MION-46L, a superparamagnetic iron oxide contrast agent, in enhancing in vivo 3D MRI sensitivity for brain lesion detection in a crEAE mouse model.
- To correlate MRI findings with histopathological data.
- To assess the potential of MION-46L-enhanced MRI in preclinical screening for MS therapies.
Main Methods:
- Administration of MION-46L to mice with crEAE.
- Acquisition of pre- and postcontrast 3D MRI scans.
- Histopathological analysis using Prussian blue iron staining to identify MION-46L distribution.
- Detection of lesions based on enhanced MRI signal and iron deposition.
Main Results:
- MION-46L dramatically enhanced lesion conspicuity on postcontrast 3D MRI compared to precontrast images.
- MION-46L was localized in vascular endothelium, perivascular space, and macrophages within inflammatory and demyelinating lesions.
- The agent enabled detection of acute early lesions as small as 100 micrometers.
- Macroscopic susceptibility effects induced by MION-46L improved detection sensitivity.
Conclusions:
- MION-46L significantly improves the sensitivity of in vivo 3D MRI for detecting brain lesions in the crEAE model.
- This enhanced imaging approach allows for detailed correlation with histopathology and aids in understanding lesion development and pathophysiology.
- MION-46L-enhanced MRI shows promise for preclinical evaluation of novel therapeutic strategies for multiple sclerosis.